Multiple System Atrophy

AskBio Announces First Patient Randomized in Phase 1 Trial of AB-1005 Gene Therapy for Multiple System Atrophy-Parkinsonian Type Asklepios BioPharmaceutical, Inc., a gene therapy firm fully owned and independently operated under Bayer AG, announced the initiation of the Phase I REGENERATE MSA-101 clinical trial ...

Multiple system atrophy (MSA) is a rare disease that affects between 15,000 and 50,000 Americans, encompassing men and women of all races. Multiple system atrophy has an unknown cause. The great majority of cases are sporadic, meaning they happen at random. The peak onset of multiple system atrophy occurs between t...